Company intelligence / Profile preview

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Shanghai, Shanghai, Chinahuilunbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Shanghai Yidian Pharmaceutical Technology Development is a private Chinese biotech company focused on the development of small molecule therapeutics for oncology and other indications. Its lead program HTMC‑0435 is a PARP inhibitor currently in Phase 2 clinical trials for advanced malignant solid neoplasms and biliary tract cancer. The company has several programs at IND/Phase 1 stages targeting various cancers and related indications. No approved products as of May 2025.

Therapeutic areas: Oncology
Modalities: Small moleculesChemical drugs
Industry: Biotech

Drug pipeline

9 assets

HL-1186

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai Yidian Pharmaceutical Technology Development Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Yidian Pharmaceutical Technology Development Co., Ltd..

Explore the full profile